Table 2. Univariate and multivariate survival analysis of clinicopathological variables in PDAC patients.

Factors	N	OS median(range)	Univariate analysis			Multivariate analysis
			HR	95%CI	P-value	HR	95%CI	P-value
Gender
Male	56	11.1(0.2-88.0)	0.58	0.33-1.03	0.07
Female	32	36.7(0.1-76.4)	1
Age
>60	47	11.3(0.2-86.7)	1.05	0.63-1.77	0.84
≤60	41	15.2(0.1-88.0)	1
T stage
T3	14	23.5(0.2-88.0)	1.03	0.50-2.09	0.95
≤T2	74	12.6(0.1-86.7)	1
N stage
N0	52	33.5(0.2-88.0)	0.69	0.53-0.90	0.006*	0.59	0.33-1.04	0.07
N1	36	9.8(0.1-86.7)	1			1
Primary tumor location
Head and Neck	58	14.8(0.1-88.0)	0.83	0.49-1.43	0.51
Body and Tail	30	10.5(1.3-79.6)	1
Lymph vascular invasion
Yes	38	10.6(0.2-82.4)	1.39	0.82-2.33	0.22
No	50	18.0(0.1-88.0)	1
Nuclear grade
≤II	73	18.4(0.2-88.0)	0.68	0.49-0.93	0.02*	0.37	0.18-0.78	0.01*
>II	15	7.0(0.1-79.6)	1			1
Jaundice
No	62	14.2(0.2-82.4)	0.98	0.55-1.74	0.94
Yes	26	11.5(0.1-88.0)	1
Abdominal pain
No	39	10.6(0.1-88.0)	0.71	0.42-1.19	0.19
Yes	49	17.6(2.7-86.7)	1
Sp1
Positive	53	9.9(0.1-88.0)	2.42	1.35-4.33	0.003*	4.48	1.14-17.62	0.03*
Negative	35	37.4(0.2-81.5)	1			1
COX2
Positive	62	10.4(0.2-88.0)	2.28	1.18-4.42	0.01*	3.84	1.08-13.71	0.04*
Negative	26	40.2(0.1-82.4)	1			1
Sp1/COX2
Sp1+/COX2+	42	10.1(0.2-88.0)	1.95	1.15-3.30	0.01*	0.33	0.07-1.55	0.16
All others	46	34.2(0.1-82.4)	1			1

Abbreviation: N, number; HR, hazard ratio; 95%CI, 95% confidence interval.

All others: Sp1+COX2-, Sp1-COX2+, and Sp1-COX2-.